Genomic Landscape of EGFR-TKI Resistance: from Known Mechanisms to Unknown Resistance

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) serve as the standard first-line therapy for advanced EGFR-mutant non-small-cell lung cancer (NSCLC). However, resistance inevitably restricts their efficacy. Although well-documented acquired resistance mechanisms have been extensively characterized, approximately 30